» Articles » PMID: 30663807

Bilateral Radiation Therapy Followed by Methotrexate-based Chemotherapy for Primary Vitreoretinal Lymphoma

Overview
Journal Am J Hematol
Specialty Hematology
Date 2019 Jan 22
PMID 30663807
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Primary vitreoretinal lymphoma (PVRL) is a subset of primary CNS lymphoma that presents as isolated ocular disease without brain involvement. Although ocular radiotherapy (RT) is an effective treatment for PVRL, the optimal treatment is uncertain. PVRL may later involve the brain in 56%-85% of patients. We report on 12 PVRL patients treated with a combination of bilateral RT and a systemic chemotherapy (CT) regimen containing high-dose methotrexate (M). Ten received RT (30-40 Gy) followed by CT, one received RT, and one was treated with intravitreal M; all achieved a complete response (CR). Three patients had tumor recurrence in the brain and received CT and one patient relapsed in the eye with a second recurrence in the brain. Three patients achieved CR-2 remain alive and one died of dementia. One died from recurrent CNS disease. With a median follow of 68 months (range, 17-154 months), median progression-free and overall survival have not been reached. Bilateral RT followed by M-based CT is an effective treatment for reducing CNS progression and prolonging survival.

Citing Articles

Comparison of various treatment modalities in patients with primary vitreoretinal lymphoma: A systematic review and meta-analysis.

Ostrovsky M, Sela T, Habot-Wilner Z Clin Exp Ophthalmol. 2024; 53(1):84-99.

PMID: 39317661 PMC: 11790420. DOI: 10.1111/ceo.14443.


Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Ferreri A, Illerhaus G, Doorduijn J, Auer D, Bromberg J, Calimeri T Hemasphere. 2024; 8(6):e89.

PMID: 38836097 PMC: 11148853. DOI: 10.1002/hem3.89.


Efficacy and safety of first-line combination therapy versus monotherapy for vitreoretinal lymphoma: a systematic review and meta-analysis.

Gao J, Peng X, Wang L BMC Ophthalmol. 2023; 23(1):477.

PMID: 37993841 PMC: 10664658. DOI: 10.1186/s12886-023-03226-3.


A comprehensive overview of diagnosis, imaging and treatment of vitreoretinal lymphoma.

Menean M, Giuffre C, Cicinelli M, Marchese A, Modorati G, Bandello F Eur J Ophthalmol. 2023; 34(4):931-940.

PMID: 37956540 PMC: 11295402. DOI: 10.1177/11206721231211931.


How I treat secondary CNS involvement by aggressive lymphomas.

Alderuccio J, Nayak L, Cwynarski K Blood. 2023; 142(21):1771-1783.

PMID: 37702537 PMC: 10862244. DOI: 10.1182/blood.2023020168.